In addition to our in-house drug discovery efforts, we strengthen our development pipeline through the active in-licensing of products and development candidates in our key therapeutic areas : hematology, intractable/rare diseases, urology and gynecology. This approach has enabled us to launch, on average, more than one new product annually.